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means differed predictably and significantly across known groups based on the PASI 
and IGA. Responsiveness effect size estimates were moderate to large (0.6 to 1.4). 
CDF plots show that the percentage of responders was consistently higher in the 
treatment arms than placebo across the range of change scores. ConClusions: 
Results support the reliability, validity, and responsiveness of the PsD and its use as 
a tool to enhance treatment decisions in patients with moderate-to-severe plaque 
psoriasis.
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The ReliabiliTy Of The PaTienT-RePORTed ScaR evaluaTiOn 
QueSTiOnnaiRe (PR-SeQ) in a cOhORT Of adulTS WiTh lineaR ScaRS
Pleil A.1, Mathias A.2, Galipeau N.2, Shields A.2, Jensen J.1
1Pfizer, Inc., San Diego, CA, USA, 2Adelphi Values, Boston, MA, USA
objeCtives: To test the reliability of the Patient Reported Scar Evaluation 
Questionnaire (PR-SEQ) in a general scar population at two time points and in two for-
mats (pen/paper and electronic). Methods: The PR-SEQ, a 30-item 4-domain meas-
ure of scar experience, was administered to a total of 512 clinic- and self-recruited 
subjects with qualifying scars. The 101 clinic-recruited subjects were administered 
the PR-SEQ in a pen/paper format at Baseline and at Timepoint 1 (T1) and Timepoint 
2 (T2) about 7 +/- 2 days apart using a computer-based version on the internet. The 
413 self-recruited subjects were administered only the internet version at T1 and T2. 
Internal consistency reliability was assessed using Cronbach’s alpha for the total T1 
cohort (n= 512); test-retest reliability was assessed using the intraclass correlation 
coefficient (ICC) based on an ANOVA model for the T1-T2 retest cohort (n= 359); and 
between forms reliability was assessed using the ICC for the clinic cohort data from 
baseline and T1 (n= 100). Results: Cronbach’s alpha was 0.96 for the PR-SEQ total 
score and 0.86 for Appearance (5 items), 0.68 for Symptoms (3 items), 0.92 for Bother (8 
items), and 0.95 for Impact (14 items) domains. The ICC for the test-retest cohort was 
0.85 for the total score and 0.76, 0.78, 0.80, and 0.81 for the domains of Appearance, 
Symptoms, Bother, and Impact, respectively. Between forms reliability was similarly 
acceptable with scores of 0.84, 0.90, 0.92, and 0.95 for the domains, and 0.94 for the 
total score. ConClusions: Overall, the two versions of the PR-SEQ demonstrated 
acceptable levels of reliability across the domains and total score, with the possible 
exception of the internal consistency of the 3-item Symptom domain. Further item 
reduction may be possible without significant risk to the reliability of the instrument.
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acuTe bacTeRial Skin and Skin STRucTuRe infecTiOn (abSSSi): 
develOPmenT Of a neW PaTienT RePORTed OuTcOme (PRO)
Powers J.H.1, Portalupi S.2, Devine J.2, Saretsky T.L.2, Hoffmann S.3, Crawley J.4, Lorens L.5, 
Cimms T.A.4, Howard K.2, FNIH Biomarkers Consortium CABP ABSSSI Project Team T6
1National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health 
(NIH), Bethesda, MD, USA, 2Oxford Outcomes, an ICON plc company, San Francisco, CA, 
USA, 3Foundation for the National Institutes of Health, Bethesda, MD, USA, 4AstraZeneca, 
Gaithersburg, MD, USA, 5Cerexa, Inc, Oakland, CA, 6Bethesda, MD, USA
objeCtives: There is a paucity of evidence regarding a well-defined, reliable, and 
feasible method for measuring efficacy outcomes in acute bacterial skin and skin 
structure infection (ABSSSI) trials. Evidence suggests a relationship between a 
decrease in lesion size and patient-centered outcomes related to pain; however, 
there is no patient reported outcome (PRO) to capture additional symptoms which 
patients may experience. The goal of this study was to explore concepts of skin 
infection as reported by patients, and comprehensively capture these symp-
toms. Methods: One-on-one telephone interviews were conducted with patients 
diagnosed with an ABSSSI within the past 4-7 days in the United States. ABSSSI 
patients with a wound infection, cellulitis (including erysipelas), or major abscess 
were included. Patients were asked to describe their skin infection and how it may 
have affected their life. The data was continually analyzed using an iterative pro-
cess to identify themes and concepts which were recorded in a saturation grid. 
Saturation was monitored according to the FDA PRO guidance. Results: Thirty-
four patients participated in concept elicitation interviews from four sites. Thirteen 
patients were diagnosed with major abscess, twelve with wound infection, and 
nine with cellulitis. Mean age of the sample was 39 years (SD = 12.2); 35% were 
female. The main themes to emerge included signs (e.g., growth, color), symptoms 
(e.g., soreness), and impacts on functionality (e.g., social, physical) related to the 
skin infection. The most commonly reported symptoms included experiencing 
pain (n= 32), swelling (n= 31), and drainage or leakage at the site of the infection 
(n= 27). ConClusions: Qualitative data gathered in the initial concept elicitation 
interviews will be combined with input from experts to form the basis of a new PRO 
instrument to assess patient-reported ABSSSI symptoms. This study will also ensure 
that the newly developed PRO instrument has established qualitative content valid-
ity for the types of ABSSSI patients being interviewed.
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QualiTaTive aSSeSSmenT Of The exPeRience Of Pain in PaTienTS WiTh 
mOdeRaTe TO SeveRe PlaQue PSORiaSiS
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objeCtives: Patients identified pain as one of the key symptoms they experience 
during early development of the Psoriasis Symptom Inventory (PSI), an 8-item meas-
ure of psoriasis symptom severity. This analysis addresses the consistency and 
relevance of pain evaluated in a supplemental qualitative study in patients with 
psoriasis. Methods: Individual concept elicitation (CE) interviews and cognitive 
interviews (CI) were conducted in adults with moderate to severe plaque psoria-
sis (Body Surface Area ≥ 10, PASI ≥ 12, Physician Global Assessment ≥ 3). Subjects 
were recruited from four different US sites. Interviews were audio-recorded and 
transcribed. Concepts were identified and coded using Atlas.ti software. Additional 
questions during the interview asked patients to rate the severity of their symptoms 
PSS27
diffeRenT PeRcePTiOnS Of QualiTy Of life amOng PSORiaSiS PaTienTS 
and TheiR TReaTing PhySicianS
Dierick K.1, Worsfold A.2, Gillis L.2, Rose A.2
1GfK Disease Atlas, Brussels, Belgium, 2GfK Disease Atlas, London, UK
objeCtives: This study aims to review whether there is a match between how pso-
riasis patients perceive their quality of life and how this is perceived by their treating 
physicians. Methods: A cross-sectional survey of Rheumatologists/Dermatologists 
(n = 114) and their psoriasis patients (n = 689) living in the United States, conducted 
June/September 2013. Each specialist completed a comprehensive record form on 
patients consulting for their psoriasis. Patients were invited to complete a question-
naire and also the EQ-5D-5L instrument. Physicians completed the same instrument 
for how they envision the status of that same patient. Patients were split into 3 equal 
groups based on their health utility scores. Results: No significant correlation was 
found between the patient- and physician-reported health utility scores (Pearson 
correlation index = - 0,071, p = 0.396). In 34% of the cases there was a significant (> 1x 
standard deviation) mismatch between the physician and the patients’ point of view. 
Out of that 34%, 20% was an overestimation (physicians scored the patients worse 
than the patients scored themselves) and 14 % was an underestimation (patients 
scored themselves worse than the physicians scored them). In 15% of the cases 
there was a perfect match (patients and physicians generated the same health 
utility score). Mismatching was most frequent in the group with the lowest health 
utility scores. ConClusions: There is no significant relationship between health 
utility scores generated by physicians and patients. Although the evaluated patient 
is the same, there appears to be a mismatch in perception of patient wellbeing.
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QualiTy Of life in PaTienTS SuffeRing fROm PSORiaSiS vulgaRiS uSing 
eQ5d; a SySTemaTic liTeRaTuRe RevieW
Moeller A.1, Erntoft S.1, Vinding G.R.2, Jemec G.B.E.2
1LEO Pharma A/S, Ballerup, Denmark, 2Roskilde Hospital, University of Copenhagen, Roskilde, 
Denmark
objeCtives: The aims of this review were 1) to estimate the disutility of patients 
suffering from psoriasis vulgaris, using the mean EQ5D index scores and 2) to com-
pare this to patients suffering from cancer (prostate, breast, Hodgkin/non-Hodgkin 
lymphoma, the digestive system) and cardiovascular diseases (angina and heart 
failure). Methods: A systematic literature search was conducted in December 2013 
in EMBASE, MEDLINE and CENTRAL using search terms EQ5D OR EQ OR EUROQoL 
AND Psoriasis AND/OR Vulgaris. The following inclusion criteria were used: original 
research, full length papers available, mild, moderate and severe psoriasis vulgaris, 
EQ5D, English written. Four independent reviewers reviewed the titles, abstracts 
and full length papers. The full length papers meeting the inclusion criteria were 
analyzed in a data extraction table. A separate search was conducted to identify 
already published systematic literature reviews in psoriasis or any other disease 
reporting on utility based on EQ5D. The results were qualitatively compared to those 
reviews. Results: In the first search, 133 titles were identified, however after 3 
rounds of reviews (excluding 65 Titles, 44 Abstracts, 7 Full length papers) 17 papers 
were found to meet the inclusion criteria. For patients suffering from psoriasis 
vulgaris the mean EQ5D-index scores ranged from 0.52 (standard deviation 0.39) 
to 0.90 (standard deviation 0.10) for all disease severities. The second search iden-
tified two systematic literature reviews one in cancer and one in cardiovascular 
diseases investigating utility based on EQ5D. Corresponding ranges for cancer and 
cardiovascular diseases are 0.33 (standard deviation 0.4) to 0.93 (standard deviation 
0.12) and 0.24 (standard deviation 0.39) to 0.90 (standard deviation 0.16) respec-
tively. ConClusions: The ranges of disutility in quality of life among patients 
suffering from psoriasis vulgaris identified in this review are within the same range 
as for patients suffering from cancer or cardiovascular diseases.
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PSychOmeTRic evaluaTiOn Of The PSORiaSiS SymPTOm diaRy uSing 
PhaSe 3 TRial daTa
Strober B.1, Zhao Y.2, Tran M.H.2, Gnanasakthy A.3, Nelson L.M.4, McLeod L.D.4, Mordin M.5, 
Gottlieb A.6, Elewski B.7, Lebwohl M.G.8
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Hanover, NJ, USA, 3Novartis Pharmaceuticals, East Hanover, NJ, USA, 4RTI Health Solutions, 
Research Triangle Park, NC, USA, 5RTI Health Solutions, Ann Arbor, MI, USA, 6Tufts Medical 
Center, Boston, MA, USA, 7University of Alabama at Birmingham, BIRMINGHAM, AL, USA, 
8Icahn School of Medicine at Mount Sinai, New York, NY, USA
objeCtives: To evaluate reliability, validity, and responsiveness of the Psoriasis 
Symptom Diary (PsD) using data from patients with moderate-to-severe chronic 
plaque-type psoriasis. Methods: Analyses were completed using pooled data from 
the screening (1-4 weeks) and induction (12 weeks) periods of two randomized, 
double-blind, double-dummy, placebo-controlled, multicenter phase 3 trials (N = 
820; CAIN457A2302 and CAIN457A2303) designed to assess the safety and efficacy 
of secukinumab. Patients aged 18+ years were randomized 1:1:1 in CAIN457A2302 
to subcutaneous treatment groups (secukinumab 150 mg, secukinumab 300 mg, 
and placebo); and 1:1:1:1 in CAIN457A2303 including an etanercept 50 mg (twice 
per week) group. The 16-item PsD (24-hour recall period; 0 to 10 numerical rat-
ing scale) was electronically administered each evening. Intraclass correlations 
were calculated to estimate test-retest reliability. Construct validity hypotheses 
were evaluated based on correlations with the Psoriasis Area and Severity Index 
(PASI), Investigator’s Global Assessment (IGA), Patient Global Impression of Change 
(PGIC), the Dermatology Life Quality Index (DLQI), and the EuroQol 5-Dimension 
Health Status Questionnaire (EQ-5D). Mean differences between known groups and 
responsiveness effect sizes were computed. Phase 2 derived anchor-based PGIC 
thresholds and cumulative distribution function (CDF) plots were used to describe 
meaningful change. Results: The PsD items yielded high intraclass coefficients (> 
0.90). Correlations were in the anticipated direction and by week 12 were moderate 
to strong (0.41 to 0.73) in magnitude, demonstrating construct validity. Item-level 
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conducted in Europe (5EU: France, Germany, Italy, Spain, and UK), Japan, US, Brazil, 
urban China, and Russia. Stratified random sampling based on sex and age (and 
ethnicity in the US) was used to ensure representativeness of the total regional 
adult populations. Quality of life (QOL) was assessed using the mental (MCS) and 
physical component summary (PCS) scores from the Short Form-12/36 (SF-12v2/
SF-36v2); work productivity loss was assessed using the Work Productivity And 
Impairment(WPAI) and health care resource use was self-reported. Descriptive 
analyses were conducted within each country; comparisons between developed and 
developing countries were made with respect to demographics, health history, and 
health outcomes. Results: The prevalence of PsO was 4.4% in 5EU, 1.0% in Japan 
and 2.4% in the US. The prevalence in developing countries was similar (Brazil 1.3%, 
Russia 2.1%, China 3.3%). Compared to those in developed countries, PsO patients 
in developing countries were more likely to be male, younger, married, employed, 
educated and have more comorbidities. Across both regions, PsO patients had lower 
scores in PCS & MCS, and higher activity impairment, work productivity loss, and 
health care resource use. The burden of PsO is associated with disease severity 
and BMI. All decrements exceeded cutoffs for clinical significance. ConClusions: 
Despite differences in patient demographics characteristics between developed and 
developing countries, significant burdens of PsO were observed across all countries 
with respect to worse QOL, higher health care resource use, and more work produc-
tivity loss than patients without PsO.
PSS36
buRden Of diSeaSe eSTimaTiOn fOR healThy aging in OldeR adulTS: 
The caSe Of The Ranking Of heaRing lOSS
Simpson K.N., Simpson A.N., Dubno J.R.
Medical University of South Carolina, Charleston, SC, USA
objeCtives: The recent Institute of Medicine (IOM) workshop on “Hearing Loss 
and Healthy Aging” brought national attention to the broad health implications of 
untreated HL in older adults. The objective of this study is to explore the impact of 
HL on quality of life (QoL) on the US population, separate from the length of sur-
vival, using the 2000 Medical Expenditure Panel Survey (MEPS) and 2010 US Census 
data. Methods: Utility weights and population modeling using data from subjects 
age 60-90 from the MEPS 2000 sample were used to estimate utility decrements 
(UD), which were then applied to the 2010 US census population to estimate annual 
QALYs lost from chronic conditions for the US population. Results: Of the sam-
ple respondents 15.4% had mild (UD.034) and 1.1% had Moderate/Severe (UD.18) 
HL. Decrements due to joint pain 53% (UD.0643), hypertension 47.2% (UD.0292), 
diabetes 15.6% (UD.0577), angina 9.8% (UD.0352), asthma 7.9% (UD.0288), emphy-
sema 4.5% (UD.1186), and age (UD.0033) were calculated. When decrements were 
applied to the population the QALY loss ranged from 821,918 for joint pain 16,614 
for blindness. Contrary to HL’s low ranking in the Global Burden of Disease study, 
HL ranked 4th at 174,689 when survival is excluded and only older US patients are 
considered. ConClusions: HL has a substantial impact on healthy aging which is 
not obvious when QoL decrements include the effects on survival, or when younger 
people are included in the estimates. It is important to disassociate the effects of 
survival and the effects of a utility decrement when discussing the burden of ill-
ness for populations for whom QoL may be more important than length of survival. 
The results raises important issues for health policy formation for the aging “Baby 
Boomer” generation, indicating that the current lack of Medicare coverage for hear-
ing aids and related services should be reassessed.
SenSORy SySTemS diSORdeRS – health care use & Policy Studies
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medicaTiOn uSe and aSSOciaTed healTh caRe cOSTS fOR fOuR cOmmOn 
Skin cOndiTiOnS in The uniTed STaTeS
Han Y.1, Balkrishnan R.2, Feldman S.R.3
1University of Michigan Ann Arbor, Ann Arbor, MI, USA, 2University of Michigan, Ann Arbor, MI, 
USA, 3Wake Forest University, Winston-Salem, NC, USA
bACkgRound: While skin disease is one of the most common health problems in 
the United States, few studies have examined the impacts of medication use for 
common skin conditions on medication cost using national representative data, 
and much of these studies are out of date. objeCtives: To examine the impact of 
patient demographics and medication use on patient’ skin conditions specific medi-
cation cost, including acne, psoriasis, contact dermatitis, and rosacea. Methods: 
This retrospective cross-sectional study was conducted using data from the 2007 
Medical Expenditure Panel Survey (MEPS) database. Information on patient demo-
graphics, health status and medication use and cost were obtained representing 
a total of 4,429,674 patients with acne; 1,489,744 patients with psoriasis; 2,621,470 
patients with contact dermatitis and 1,214,775 patients with rosacea. Results: 
The weighted average annual total medication payments associated with specific 
conditions was about $183 for patients with acne; $3036 for patients with psoria-
sis; $62 for patients with contact dermatitis and $307 for patients with rosacea. 
Results of weighted multiple linear regression indicated that refill times of pre-
scribed medications were significantly related with higher medication expenditure 
for all of four skin conditions (prefill< 0.001). Being covered by private or public insur-
ance yielded an increase in medication expenditure except for psoriasis patients 
(acne: pprivate< 0.05, contact dermatitis: pprivate< 0.01, rosacea: pprivate< 0.01). Older 
adults with acne or contact dermatitis expended less on medication compared with 
younger adults (acne: page< 0.01, contact dermatitis: page< 0.05). ConClusions: By 
calculating the annual total medication expenditures, this study provides impor-
tant up-to-date information on the economic burden of these four common skin 
conditions. Results of this study indicated medication use and being covered by 
insurance were associated with medication expenditure. Expanding the coverage 
of insurance may increase medication spending for patients with skin conditions, 
thus impact of insurance coverage and medication use on patient health status 
needs further studies.
on a scale of 0 to 10. Relevance of pain to the patient experience with psoriasis 
was assessed using the patients’ descriptive language to identify related themes 
and assign codes to similar content. Resulting concept codes were evaluated for 
predominance (how much patients talked about each concept), severity, and being 
offered spontaneously. Results: The 30 subjects interviewed (CE, N= 20; CI, N= 10) 
were between 27 and 75 years of age (mean of 52), and were 30% female and 60% 
white. Concept codes for pain comprised 11% of all the expressions patients offered 
about their symptoms. Pain was the fourth most predominantly discussed symptom 
in the interview transcripts. In 11 of the 20 CE interviews subjects spontaneously 
offered pain as a symptom and rated its severity as 6.2 out of 10. ConClusions: 
These qualitative findings regarding the presence and severity of pain provide evi-
dence for the inclusion of pain as a key symptom concept of relevance to patients 
with moderate to severe psoriasis.
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develOPmenT Of a PaTienT-RePORTed OuTcOmeS meaSuRe fOR PSORiaSiS: 
The PSORiaSiS SymPTOmS, SignS, and imPacT QueSTiOnnaiRe
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objeCtives: To develop a patient-reported outcome (PRO) questionnaire meas-
uring symptoms, signs, and impact to assess treatment benefit in patients with 
moderate-severe plaque psoriasis(PsO). Methods: In-person 1:1 concept elicitation 
interviews were conducted to identify concepts relevant and important to moder-
ate-severe PsO patients (n = 20). An interview guide was designed to obtain input 
regarding symptoms, signs, impact on work, family and general well-being, and spe-
cific language to express issues related to having plaque PsO. Evidence of saturation 
was determined when no new concepts were mentioned. From these results, input 
from dermatologists, PRO experts, and published literature, a Psoriasis Symptoms, 
Signs and Impact Questionnaire (PSSIQ) was drafted. The PSSIQ was revised based 
on three waves of in-person cognitive debriefing interviews with moderate-severe 
plaque PsO patients (n = 19), and consideration of translatability into non-English 
languages. Results: The PSSIQ contains two sections. A Psoriasis Symptoms and 
Signs Diary (PSSD) includes 5 symptoms (itch, pain, stinging, burning, and skin 
tightness) and 6 patient observable signs (skin dryness, cracking, scaling, shedding 
or flaking, redness, and bleeding) using 0-10 numerical rating scales for severity. 
The second section, the Psoriasis Impact Questionnaire, includes items on impact 
of psoriasis on daily activities and emotional impact during the past 7 days. Two 
versions are available using a recall period of either the past 24 hours or past 7 days. 
Days with symptoms and signs experienced are collected in the 7-day version. 
During cognitive interviews, PsO patients found each item and the instructions in 
the questionnaire clear and relevant, and were able to provide a response with rela-
tive ease. ConClusions: The PSSIQ will be a valuable tool to evaluate treatment 
benefits of new therapeutic agents for patients with moderate-severe plaque PsO in 
clinical trials. Research examining its measurement properties, including reliability, 
validity, and ability to detect change, is underway.
PSS34
viSual funcTiOn ReSPOnSe TO OcRiPlaSmin fOR The TReaTmenT Of 
viTReOmaculaR TRacTiOn and maculaR hOle
Jackson T.1, Verstraeten T.2, Duchateau L.3, Lescrauwaet B.4
1King’s College Hospital, London, UK, 2P95, Leuven, Belgium, 3Ghent University, Ghent, Belgium, 
4Xintera Ltd., London, UK
objeCtives: Vitreomacular adhesion (VMA) can lead to pathologic traction and 
macular hole formation. The effect of an intravitreal ocriplasmin-injection on VMA 
resolution was demonstrated in two multicentre, randomized, double-masked, 
phase 3 clinical trials (MIVI-TRUST). The objective of our analysis was to assess the 
effect of ocriplasmin on patient relevant visual function outcomes, measured using 
visual acuity (VA) and vision-related quality of life. Methods: Post-hoc analysis of 
prespecified secondary endpoints in MIVI-TRUST. A total of 652 participants with 
symptomatic VMA were enrolled, of whom 464 received a single intravitreal injec-
tion of 125µg ocriplasmin and 188 received a single intravitreal placebo-injection. 
Visual function response (VFR) was defined as either: a VA improvement of ≥ 2 lines; 
or an improvement exceeding the minimal clinically important difference (MCID) 
in the composite score of the National Eye Institute Visual Function Questionnaire 
(VFQ-25) or in the VFQ-25 driving subscale score. The MCID was estimated using 
the standard error of measurement approach. The main outcome measure was the 
VFR at 6 months. Results: The MCID was estimated at 3.6 points for the VFQ-25 
composite score and 19.1 for the VFQ-25 driving subscale score. A VFR occurred in 
55.1 % of the ocriplasmin-injection group versus 34.2% of the placebo-injection 
group (P< 0.0001). This comprised 23.7% versus 11.2% (P= 0.0003) with a ≥ 2 line 
VA improvement, 35.9% versus 22.7% (P= 0.0016) for the VFQ-25 composite score 
increase > MCID, and 10.2 % versus 6.2% (P= 0.1697) for the driving subscale score 
increase > MCID. ConClusions: Ocriplasmin produces significant and clinically 
meaningful visual function benefit to the patient in addition to higher VMA resolu-
tion rates. This analysis redefines visual function response and allows patient and 
physician to consider both anatomical and functional benefits when discussing 
treatment options.
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buRden Of PSORiaSiS in develOPing and develOPed cOunTRieS
Tang B.1, Annunziata K.2, DiBonaventura M.2
1Pfizer, Inc., New York, NY, USA, 2Kantar Health, Princeton, NJ, USA
objeCtives: To evaluate the burden of psoriasis (PsO) in developed (Europe, US, 
and Japan) and developing countries (Brazil, China, and Russia). Methods: The 
analysis utilized data from the 2011 and 2012 National Health and Wellness Survey 
(NHWS, validated/stored by Kantar Health, USA) an annual cross-sectional survey 
